These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 20381630

  • 1. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M, Molimard M.
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [Abstract] [Full Text] [Related]

  • 2. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
    Calzetta L, Matera MG, Cazzola M.
    Eur J Pharmacol; 2015 Aug 15; 761():168-73. PubMed ID: 25981302
    [Abstract] [Full Text] [Related]

  • 4. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA, Donohue JF.
    Semin Respir Crit Care Med; 2010 Jun 15; 31(3):321-33. PubMed ID: 20496301
    [Abstract] [Full Text] [Related]

  • 5. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?
    Reddy CB, Kanner RE.
    Drugs Aging; 2007 Jun 15; 24(8):615-28. PubMed ID: 17702532
    [Abstract] [Full Text] [Related]

  • 6. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 15; 10():1093-102. PubMed ID: 26089659
    [Abstract] [Full Text] [Related]

  • 7. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH, Rabe KF, Welte T.
    Pulm Pharmacol Ther; 2017 Aug 15; 45():19-33. PubMed ID: 28389258
    [Abstract] [Full Text] [Related]

  • 8. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
    Kume H.
    Nihon Rinsho; 2016 May 15; 74(5):813-9. PubMed ID: 27254952
    [Abstract] [Full Text] [Related]

  • 9. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH, Chang CH, Gagne JJ, Hsu CL, Lai MS.
    Pharmacotherapy; 2016 Jan 15; 36(1):26-37. PubMed ID: 26799347
    [Abstract] [Full Text] [Related]

  • 10. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
    Mastrodicasa MA, Droege CA, Mulhall AM, Ernst NE, Panos RJ, Zafar MA.
    Expert Opin Investig Drugs; 2017 Feb 15; 26(2):161-174. PubMed ID: 28004591
    [Abstract] [Full Text] [Related]

  • 11. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
    Rabe KF.
    Expert Rev Clin Pharmacol; 2017 Jul 15; 10(7):685-698. PubMed ID: 28443352
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
    Di Marco F, Santus P, Scichilone N, Solidoro P, Contoli M, Braido F, Corsico AG.
    Respir Med; 2017 Apr 15; 125():49-56. PubMed ID: 28340862
    [Abstract] [Full Text] [Related]

  • 15. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM, Beier J.
    Adv Ther; 2010 Mar 15; 27(3):150-9. PubMed ID: 20411368
    [Abstract] [Full Text] [Related]

  • 16. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
    Fuso L, Mores N, Valente S, Malerba M, Montuschi P.
    Curr Med Chem; 2013 Mar 15; 20(12):1477-95. PubMed ID: 23409722
    [Abstract] [Full Text] [Related]

  • 17. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
    Malerba M, Radaeli A, Montuschi P, Babu KS, Morjaria JB.
    Expert Opin Investig Drugs; 2017 Mar 15; 26(3):319-329. PubMed ID: 28117615
    [Abstract] [Full Text] [Related]

  • 18. Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.
    Hughes AD, Jones LH.
    Future Med Chem; 2011 Oct 15; 3(13):1585-605. PubMed ID: 21942250
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.